Infex Therapeutics
Infex Therapeutics is a UK-based specialist engaged in the acquisition, development, and licensing of drugs targeting pandemic and critical-priority infectious diseases, including both bacterial and viral threats. The company has a focus on combating antimicrobial resistance (AMR) by progressing new therapies for life-threatening infections into clinical trials. Infex Therapeutics works collaboratively with global partners, leveraging a robust R&D infrastructure at Alderley Park, and is involved in industry partnerships, public-private initiatives, and clinical-stage development.
Industries
N/A
Patents
1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors
2026-02-10 • US-12544359-B2
View Details
1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors
2026-02-10 • US-12544359-B2
View DetailsProducts
A monoclonal antibody therapeutic targeting the type III secretion system of P. aeruginosa to support treatment of chronic lung infections.
A small molecule inhibitor to restore the efficacy of β-lactam antibiotics against bacteria with metallo-β-lactamase enzymes.
Development of hybrid molecules combining different antibiotic classes to improve efficacy against resistant bacteria.
Development and optimization of synthetic peptides with activity against Gram-negative drug-resistant bacteria.
A monoclonal antibody therapeutic targeting the type III secretion system of P. aeruginosa to support treatment of chronic lung infections.
A small molecule inhibitor to restore the efficacy of β-lactam antibiotics against bacteria with metallo-β-lactamase enzymes.
Development of hybrid molecules combining different antibiotic classes to improve efficacy against resistant bacteria.
Development and optimization of synthetic peptides with activity against Gram-negative drug-resistant bacteria.
Services
Support for early-stage discovery, hit-to-lead optimization, mechanism studies, and preclinical candidate nomination for anti-infectives.
Management or co-management of early phase clinical trials for new anti-infective drugs, including patient enrolment and monitoring.
Support for early-stage discovery, hit-to-lead optimization, mechanism studies, and preclinical candidate nomination for anti-infectives.
Management or co-management of early phase clinical trials for new anti-infective drugs, including patient enrolment and monitoring.
Expertise Areas
- Antimicrobial resistance therapeutics
- Critical-priority pathogen drug development
- Collaborative drug discovery partnerships
- Platform development for infectious disease
Key Technologies
- Antimicrobial peptides
- Monoclonal antibody therapeutics
- Metallo-β-lactamase enzyme inhibition
- Hybrid antibiotic molecules
Key People
Executive Director
Chief Operating Officer
Head of Biology
Senior Microbiologist
Microbiologist
DMPK Outsourcing Manager
Executive Director
Chief Operating Officer
Head of Biology
Senior Microbiologist
Microbiologist
DMPK Outsourcing Manager
News & Updates
Received £4.55 million in government funding over five years as part of a larger regional consortium to support anti-infective R&D.
Became an associated member of a European alliance of biotech companies combating antimicrobial resistance.
Sponsored the Research Category Award recognising contributions to the fight against antibiotic resistance.
Provided input and expert opinion on combating antibiotic resistance to governmental advisory body.
Announced advancement of a small-molecule MBL inhibitor to preclinical development targeting resistant Gram-negative pathogens.
Received major funding from LifeArc and other investors to accelerate new drug development.
Received £4.55 million in government funding over five years as part of a larger regional consortium to support anti-infective R&D.
Became an associated member of a European alliance of biotech companies combating antimicrobial resistance.
Sponsored the Research Category Award recognising contributions to the fight against antibiotic resistance.
Provided input and expert opinion on combating antibiotic resistance to governmental advisory body.
Announced advancement of a small-molecule MBL inhibitor to preclinical development targeting resistant Gram-negative pathogens.
Received major funding from LifeArc and other investors to accelerate new drug development.